Live feed15:55:00·109dPRReleasevia QuantisnowJohnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second LineByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
